Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia

David M. Loeb, Daniel C. Bowers, Curt I. Civin, Alan D. Friedman

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background. Timed sequential chemotherapy and high-dose cytarabine (cytosine arabinoside, Ara-C; HDAC) are both effective treatments for acute myeloid leukemia (AML). We review our institutional experience with timed sequential induction chemotherapy consisting of daunorubicin/Ara-C/-thioguanine (DAT) or idarubicin/Ara-C/-thioguanine (IAT) followed on day 14 by HDAC regardless of the degree of marrow aplasia for children with newly diagnosed AML. Procedure. Children presenting with newly diagnosed AML were treated with induction chemotherapy consisting of idarubicin (12 mg/m2/day on days 1-3 or daunorubicin at 45 mg/m2/day for the first five patients), Ara-C (100 mg/m2/day by continuous infusion on days 1-7), and thioguanine (100 mg/m2/day on days 1-7). HDAC (1 g/m2/ dose every 12 hr for 10 doses) was administered beginning on day 14, regardless of the results of bone marrow examination. Results. Thirteen children received timed sequential HDAC. Only one child received HDAC later than Day 18. Eleven of the children achieved a complete remission. All patients experienced grade 4 hematologic toxicity, and all had fever as well. There were 11 children with documented infections. Ten had grade 3 or 4 GI toxicity. One patient died of sepsis. Conclusions. HDAC administered as a part of timed sequential therapy yields an excellent remission induction rate with manageable toxicity.

Original languageEnglish (US)
Pages (from-to)365-371
Number of pages7
JournalMedical and Pediatric Oncology
Volume37
Issue number4
DOIs
StatePublished - 2001

Fingerprint

Remission Induction
Induction Chemotherapy
Cytarabine
Acute Myeloid Leukemia
Thioguanine
Idarubicin
Daunorubicin
Bone Marrow Examination
Sepsis
Fever
Bone Marrow
Drug Therapy
Therapeutics
Infection

Keywords

  • AML
  • Cytarabine
  • High dose Ara-C
  • Timed sequential therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia. / Loeb, David M.; Bowers, Daniel C.; Civin, Curt I.; Friedman, Alan D.

In: Medical and Pediatric Oncology, Vol. 37, No. 4, 2001, p. 365-371.

Research output: Contribution to journalArticle

@article{27abf270d16e4c5389710b2cb1799e0c,
title = "Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia",
abstract = "Background. Timed sequential chemotherapy and high-dose cytarabine (cytosine arabinoside, Ara-C; HDAC) are both effective treatments for acute myeloid leukemia (AML). We review our institutional experience with timed sequential induction chemotherapy consisting of daunorubicin/Ara-C/-thioguanine (DAT) or idarubicin/Ara-C/-thioguanine (IAT) followed on day 14 by HDAC regardless of the degree of marrow aplasia for children with newly diagnosed AML. Procedure. Children presenting with newly diagnosed AML were treated with induction chemotherapy consisting of idarubicin (12 mg/m2/day on days 1-3 or daunorubicin at 45 mg/m2/day for the first five patients), Ara-C (100 mg/m2/day by continuous infusion on days 1-7), and thioguanine (100 mg/m2/day on days 1-7). HDAC (1 g/m2/ dose every 12 hr for 10 doses) was administered beginning on day 14, regardless of the results of bone marrow examination. Results. Thirteen children received timed sequential HDAC. Only one child received HDAC later than Day 18. Eleven of the children achieved a complete remission. All patients experienced grade 4 hematologic toxicity, and all had fever as well. There were 11 children with documented infections. Ten had grade 3 or 4 GI toxicity. One patient died of sepsis. Conclusions. HDAC administered as a part of timed sequential therapy yields an excellent remission induction rate with manageable toxicity.",
keywords = "AML, Cytarabine, High dose Ara-C, Timed sequential therapy",
author = "Loeb, {David M.} and Bowers, {Daniel C.} and Civin, {Curt I.} and Friedman, {Alan D.}",
year = "2001",
doi = "10.1002/mpo.1212",
language = "English (US)",
volume = "37",
pages = "365--371",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia

AU - Loeb, David M.

AU - Bowers, Daniel C.

AU - Civin, Curt I.

AU - Friedman, Alan D.

PY - 2001

Y1 - 2001

N2 - Background. Timed sequential chemotherapy and high-dose cytarabine (cytosine arabinoside, Ara-C; HDAC) are both effective treatments for acute myeloid leukemia (AML). We review our institutional experience with timed sequential induction chemotherapy consisting of daunorubicin/Ara-C/-thioguanine (DAT) or idarubicin/Ara-C/-thioguanine (IAT) followed on day 14 by HDAC regardless of the degree of marrow aplasia for children with newly diagnosed AML. Procedure. Children presenting with newly diagnosed AML were treated with induction chemotherapy consisting of idarubicin (12 mg/m2/day on days 1-3 or daunorubicin at 45 mg/m2/day for the first five patients), Ara-C (100 mg/m2/day by continuous infusion on days 1-7), and thioguanine (100 mg/m2/day on days 1-7). HDAC (1 g/m2/ dose every 12 hr for 10 doses) was administered beginning on day 14, regardless of the results of bone marrow examination. Results. Thirteen children received timed sequential HDAC. Only one child received HDAC later than Day 18. Eleven of the children achieved a complete remission. All patients experienced grade 4 hematologic toxicity, and all had fever as well. There were 11 children with documented infections. Ten had grade 3 or 4 GI toxicity. One patient died of sepsis. Conclusions. HDAC administered as a part of timed sequential therapy yields an excellent remission induction rate with manageable toxicity.

AB - Background. Timed sequential chemotherapy and high-dose cytarabine (cytosine arabinoside, Ara-C; HDAC) are both effective treatments for acute myeloid leukemia (AML). We review our institutional experience with timed sequential induction chemotherapy consisting of daunorubicin/Ara-C/-thioguanine (DAT) or idarubicin/Ara-C/-thioguanine (IAT) followed on day 14 by HDAC regardless of the degree of marrow aplasia for children with newly diagnosed AML. Procedure. Children presenting with newly diagnosed AML were treated with induction chemotherapy consisting of idarubicin (12 mg/m2/day on days 1-3 or daunorubicin at 45 mg/m2/day for the first five patients), Ara-C (100 mg/m2/day by continuous infusion on days 1-7), and thioguanine (100 mg/m2/day on days 1-7). HDAC (1 g/m2/ dose every 12 hr for 10 doses) was administered beginning on day 14, regardless of the results of bone marrow examination. Results. Thirteen children received timed sequential HDAC. Only one child received HDAC later than Day 18. Eleven of the children achieved a complete remission. All patients experienced grade 4 hematologic toxicity, and all had fever as well. There were 11 children with documented infections. Ten had grade 3 or 4 GI toxicity. One patient died of sepsis. Conclusions. HDAC administered as a part of timed sequential therapy yields an excellent remission induction rate with manageable toxicity.

KW - AML

KW - Cytarabine

KW - High dose Ara-C

KW - Timed sequential therapy

UR - http://www.scopus.com/inward/record.url?scp=0034799047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034799047&partnerID=8YFLogxK

U2 - 10.1002/mpo.1212

DO - 10.1002/mpo.1212

M3 - Article

VL - 37

SP - 365

EP - 371

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -